All In Biotech

Drug Trial Radar · NCT02679456

Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

Last checked: Nov 20, 2026Latest source record: Jul 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

Nov 2015

Primary completion

Aug 5, 2016

Study completion Aug 5, 2016

Sponsor

Lead sponsor
Scynexis, Inc.Industry
Sponsor type
Industry
Collaborators
ethica Clinical Research Inc.
First posted
Feb 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multicenter, evaluator blinded study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SCY-078 compared to Fluconazole in adult patients with moderate to severe Vulvovaginal Candidiasis (VVC) and a history of frequent episodes of VVC. Approximately 90 subjects, meeting the inclusion criteria will be enrolled and randomized in a 1:1:1 ratio to one of the 3 treatment arms: Oral SCY-078 in 2 dose regimens or oral Fluconazole. After enrollment, subjects will be evaluated on Day-5 (end of treatment visit), Day-24 (test of cure visit), Day-60, Day 90 and Day 120 (end of observation period visit) or at any time that a recurrence or clinical failure is suspected, up to the end of observation period.

Conditions

  • Vulvovaginal Candidiasis

Interventions

  • SCY-078Drug

  • FluconazoleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving therapeutic cure at the test of cure visit (Day 24 +/-3)Time frame: Day 24 +/- 3

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Dr. Francisco E. Moscoso Puello

    Santo Domingo, Dominican Republic

  • Instituto Dermatologico y Cirugia de Piel

    Santo Domingo, Dominican Republic

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.